Haiyan Xu

发表

Osimertinib for Chinese advanced non-small cell lung cancer patients harboring diverse EGFR exon 20 insertion mutations.

Y. Zhang, Yan Wang, Guo-hui Li, 2020, Lung cancer.

Genomic profile and immune microenvironment in patients with relapsed stage IA lung adenocarcinoma

J. Ying, Junling Li, Yan Wang, 2020, Translational oncology.

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

N. Sun, Jie He, Yan Wang, 2022, BMC Medicine.

Treatment outcome and clinical characteristics of HER2 mutated advanced non‐small cell lung cancer patients in China

Yan Wang, Fei Xu, Lu Yang, 2019, Thoracic cancer.

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients

Shuyang Zhang, Yan Wang, Shucai Zhang, 2021, Cancer medicine.

Specific HER2 Exon 20 Gly776 Deletion-Insertions in Non-Small Cell Lung Cancer: Structural Analysis and Sensitivity to HER2-Targeted Tyrosine Kinase Inhibitors

Shuyang Zhang, Junling Li, Yan Wang, 2022, Frontiers in Pharmacology.

KRAS‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer

N. Sun, Q. Xue, Yan Wang, 2022, Cancer communications.

First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2-altered NSCLC: a retrospective real-world POLISH study

Shuyang Zhang, P. Xing, Junling Li, 2022, Therapeutic advances in medical oncology.

Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: a retrospective real-world study (PEARL)

Shuyang Zhang, Junling Li, Yan Wang, 2021, Journal of the National Cancer Center.

Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: a prospective, open-label, single-arm phase 2 study (PATHER2)

P. Xing, Junling Li, Yan Wang, 2022, BMC Medicine.

Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis

Jiang Li, Haiyan Xu, Yanfeng Wang, 2019, Journal of cancer research and therapeutics.

Systematic analysis of IL-6 as a predictive biomarker and desensitizer of immunotherapy responses in patients with non-small cell lung cancer

N. Sun, Jie He, Yan Wang, 2022, BMC Medicine.

Adjuvant chemotherapy in patients with recurrence after completely resected stage IB lung adenocarcinoma: Propensity‐matched analysis in a cohort of 147 recurrences

J. Ying, P. Xing, Junling Li, 2022, Thoracic cancer.

Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy

Haiyan Xu, Tao Wang, 2022, Exploration of Medicine.

[Explore the Optimal Resolvent of Medical Needs and Mental Health for Patients with Lung Cancer during Epidemic Novel Coronavirus Pneumonia].

Yan Wang, Lu Yang, Dan Wang, 2020, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

EGFR exon 20 insertion variants A763_Y764insFQEA and D770delinsGY confer favorable sensitivity to currently approved EGFR-specific tyrosine kinase inhibitors

Yan Wang, Yaning Yang, Haiyan Xu, 2022, Frontiers in Pharmacology.

Afatinib and Dacomitinib Efficacy, Safety, Progression Patterns, and Resistance Mechanisms in Patients with Non-Small Cell Lung Cancer Carrying Uncommon EGFR Mutations: A Comparative Cohort Study in China (AFANDA Study)

X. Yan, P. Xing, X. Hao, 2022, Cancers.

Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China

X. Yan, Jun-ling Li, Yan Wang, 2022, Frontiers in Pharmacology.

A real‐world study of dacomitinib in later‐line settings for advanced non‐small cell lung cancer patients harboring EGFR mutations

X. Yan, P. Xing, Yan Wang, 2022, Cancer medicine.

EGFR Exon 18 Mutations in Advanced Non-Small Cell Lung Cancer: A Real-World Study on Diverse Treatment Patterns and Clinical Outcomes

P. Xing, Junling Li, Yan Wang, 2021, Frontiers in Oncology.

A Linear Discriminant Analysis Model Based on the Changes of 7 Proteins in Plasma Predicts Response to Anlotinib Therapy in Advanced Non-Small Cell Lung Cancer Patients

Yan Wang, Lu Yang, Xueying Wu, 2022, Frontiers in Oncology.

EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.

S. Ou, J. Ying, Yan Wang, 2020, Lung cancer.

First‐line immunotherapy or angiogenesis inhibitor combined with chemotherapy for advanced non‐small cell lung cancer with EGFR exon 20 insertions: Real‐world evidence from China

Junling Li, Yan Wang, X. Hao, 2022, Cancer medicine.

The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.

N. Sun, Jie He, Zhiliang Lu, 2020, Cancer letters.

Treatment patterns and outcomes of immunotherapy in extensive‐stage small‐cell lung cancer based on real‐world practice

Yan Wang, X. Hao, Yaning Yang, 2022, Thoracic cancer.

Tumor Differentiation and EGFR Mutation Associated with Disease-Free Survival in Stage IA Lung Adenocarcinoma Patients with Curative Surgery

Changli Wang, Yan Wang, Lu Yang, 2020, Cancer management and research.

The value of blood biomarkers of progression and prognosis in ALK‐positive patients with non–small cell lung cancer treated with crizotinib

Junling Li, Yan Wang, Yaning Yang, 2019, Asia-Pacific journal of clinical oncology.

The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors

N. Sun, Jie He, Yan Wang, 2022, Frontiers in Oncology.

Crizotinib vs platinum‐based chemotherapy as first‐line treatment for advanced non‐small cell lung cancer with different ROS1 fusion variants

J. Ying, Junling Li, Yan Wang, 2020, Cancer medicine.

Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

P. Xing, Junling Li, Yan Wang, 2019, Cancer medicine.

Sequential therapy according to distinct disease progression patterns in advanced ALK-positive non-small-cell lung cancer after crizotinib treatment

P. Xing, Junling Li, Yan Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations

J. Ying, Junling Li, Yan Wang, 2020, Targeted Oncology.

The prognostic value of a Methylome-based Malignancy Density Scoring System to predict recurrence risk in early-stage Lung Adenocarcinoma

S. Chuai, J. Ying, Junling Li, 2020, Theranostics.

Osimertinib for the treatment of epidermal growth factor receptor-mutated non-small cell lung cancer patients with leptomeningeal metastases and different T790M status

Yan Wang, Shan Liu, Lu Yang, 2021, Annals of translational medicine.

Superior efficacy of immunotherapy‐based combinations over monotherapy for EGFR‐mutant non‐small cell lung cancer acquired resistance to EGFR‐TKIs

Yan Wang, X. Hao, Zhijie Wang, 2020, Thoracic cancer.

Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis

Yan Wang, Shufei Yu, G. An, 2023, BMJ Open.

Exosomal miR-375-3p breaks vascular barrier and promotes small cell lung cancer metastasis by targeting claudin-1

N. Sun, Jie He, Zhiliang Lu, 2021, Translational lung cancer research.

Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review

P. Xing, Jun-ling Li, Yan Wang, 2022, Frontiers in Immunology.

Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.

Shuyang Zhang, Yan Wang, Yaning Yang, 2020, Lung cancer.

EGFR uncommon alterations in advanced non-small cell lung cancer and structural insights into sensitivity to diverse tyrosine kinase inhibitors

P. Xing, Junling Li, Yan Wang, 2022, Frontiers in Pharmacology.

Making the Best Use of Available Weapons for the Inevitable Rivalry-Resistance to EGFR-TKIs

N. Sun, Yan Wang, Jie He, 2023, Biomedicines.

Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance

P. Xing, Junling Li, Yan Wang, 2019, Thoracic cancer.

甲氨蝶呤鞘内注射治疗脑膜癌病疗效和安全性的临床观察

Junling Li, J. Wan, Haiyan Xu, 2016, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Study Protocol for the Evaluation of Individual Psychological Interventions for Family Caregivers of Advanced Cancer Patients

Jiang Li, M. Cong, F. Ma, 2021, Frontiers in Psychology.

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer

P. Xing, Yan Wang, X. Hao, 2023, Thoracic cancer.

The Superior Efficacy of Anti-PD-1/PD-L1 Immunotherapy in KRAS-Mutant Non-Small Cell Lung Cancer that Correlates with an Inflammatory Phenotype and Increased Immunogenicity

N. Sun, Jie He, Zhiliang Lu, 2019, SSRN Electronic Journal.

Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants

Jiagen Li, Zhe-feng Liu, J. Ying, 2019, Annals of Oncology.

Real-world treatment outcome of advanced Chinese NSCLC EGFR exon 20 insertion patients.

S. Ou, Yan Wang, Yaning Yang, 2019, Journal of Clinical Oncology.

The efficacy and safety of chemo‐free therapy in epidermal growth factor receptor tyrosine kinase inhibitor‐resistant advanced non‐small cell lung cancer: A single‐arm, phase II study

Yan Wang, Yaning Yang, L. Yang, 2023, Cancer medicine.

Comparing first‐line treatment patterns and clinical outcomes of patients with pan‐negative advanced non‐squamous non‐small cell lung cancer

Wenjie Zhu, J. Ying, Yan Wang, 2018, Thoracic cancer.

A Study on the Drug Concentration in Fellow Eyes After Unilateral Intravitreal Injection of Conbercept Into New Zealand Rabbit Eyes

Junjie Ye, Y. Di, Haiyan Xu, 2021, Frontiers in Pharmacology.

Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study

Yan Wang, Xingsheng Hu, Haiyan Xu, 2021, Journal of Thoracic Disease.